News | July 09, 2009

Economy Forces European Institutions to Select Lower-Priced Interventional Cardiology Devices

July 9, 2009 – According to Millennium Research Group (MRG), the ongoing economic crisis is putting pressure on publicly funded European healthcare systems, intensifying the decline of interventional cardiology device prices in the region.

MRG's “European Markets for Interventional Cardiology Devices 2009 (Part II)” report details the extent to which competitive pricing and discounts among interventional cardiology device vendors is resulting in price erosion in Belgium, Luxembourg, the Netherlands, Norway, Denmark, Finland, Sweden, Spain and Switzerland.

IC device vendors are engaging in price undercutting and offering high-volume discounts or bundling deals with other products in their portfolios in order to encourage sales, resulting in price erosion. The healthcare systems in the Netherlands and Switzerland (beginning in 2012) provide only general funding for IC procedures, despite the varying cost of devices used. In order to operate within set budgets, European healthcare facilities must often choose lower-cost devices. Contract tenders between sellers and group purchasing organizations will further add to price erosion. In exchange for high-volume sales of their products, manufacturers offer significant discounts. This method of business is becoming more common across Europe, particularly in the Nordic countries and Spain.

MRG's new report provides important insight into the reasons behind and extent of the changes in interventional cardiology device pricing. Additionally, the report provides full breakdowns of procedures by type and device unit sales by subtype, including five-year forecasts, up-to-date market shares and in-depth qualitative insights.

For more information: www.MRG.net

Related Content

Philips Showcases Integrated Solutions for Cardiovascular Care at TCT 2018
News | Cath Lab | September 20, 2018
At the Transcatheter Cardiovascular Therapeutics (TCT) annual meeting, Sept. 21–25 in San Diego, Philips is showcasing...
Sponsored Content | Videos | Cath Lab | September 19, 2018
William O’Neill, M.D., outlines his recent clinical publication of AMICS patients from the Impella Quality (IQ) datab
Videos | Cath Lab | September 14, 2018
A discussion with Nicolas Bevins, Ph.D., vice chair, physics and research, and Jessica Harrington, RCIS.
A complex PCI case to revascularize a chronic total occlusion (CTO) at Henry Ford Hospital in Detroit. Complex PCI and CHIP cases are increasing patient volumes in the cath lab and using a minimally invasive approach in patients who otherwise would have been sent for CABG. Pictured is Khaldoon Alaswad, M.D. DAIC staff photo by Dave Fornell

A complex PCI case to revascularize a chronic total occlusion (CTO) at Henry Ford Hospital in Detroit. Complex PCI and CHIP cases are increasing patient volumes in the cath lab and using a minimally invasive approach in patients who otherwise would have been sent for CABG. Pictured is Khaldoon Alaswad, M.D. (right) who is proctoring a fellow in treating CTOs.

Feature | Cath Lab | September 13, 2018 | Artur Kim, Kamran Zamanian
Coronary artery disease (CAD) is a multifaceted disease that demands various approaches in terms of diagnosis and tre
Videos | Cath Lab | August 13, 2018
Jeffrey Schussler, M.D., FACC, FSCAI, FSCCT, FACP, interventional cardiologist at Baylor Scott White Heart and Vascul
Shockwave Launches Coronary Intravascular Lithotripsy in Europe
News | Cath Lab | May 30, 2018
Shockwave Medical recently announced the European commercial availability of Intravascular Lithotripsy (IVL) for...
FFR software on the GE Centricity CVIS. A trial from the 2018 EuroPCR meeting showed FFR improves long-term outcomes.
News | Cath Lab | May 29, 2018
May 29, 2018 — Ongoing controversy exists regarding the role of percutaneous coronary intervention (PCI) for stable c
SCAI Updates Consensus on Length of Stay for Percutaneous Coronary Intervention
News | Cath Lab | May 15, 2018
Revised guidelines incorporating new data on discharge criteria for patients undergoing elective percutaneous coronary...
No Benefit Found Using Sodium Bicarbonate, Acetylcysteine to Prevent Kidney Injury, the result of the PRESERVE Trial to prevent acute kidney injury (AKI), presented at SCAI 2018.  #SCAI, #SCAI2018,
Feature | Cath Lab | May 15, 2018
May 15, 2018 – The large-scale, international randomized PRESERVE clinical trial found high-risk patients for renal c
Angiogram of a STEMI patient.
News | Cath Lab | May 15, 2018
May 15, 2018 — A contemporary, real-world analysis shows lower mortality rates when culprit-only intervention is used
Overlay Init